Skip to main content
main-content

02-06-2019 | Prostate cancer | Video

ASCO 2019: TITAN shows survival benefit with apalutamide in metastatic CSPC

Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).

Funding for independent interviews at ASCO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits